Wall Street analyst estimates for Oscar Health, Inc. (OSCR): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
Oscar Health, Inc. operates as a health insurance provider across the United States. Its offerings include various health plans such as those for individuals and families, small businesses, and Medicare Advantage options. The company also features "+Oscar," a proprietary technology platform designed to facilitate engagement between healthcare providers, payers, and their members or patients. Additionally, Oscar Health provides reinsurance solutions.
Consensus price target
$37.43 (+23 % vs price $30.37)
between $20.00 and $49.00 · 11 targets published in the last quarter
Closing price, Oct 30
A twelve-month target is not a fair value: compare it with the range in the Valuation tab.
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2026E | $18.6B | $18.6B – $18.7B | $1.93 | 6 |
| 2027E | $20.9B | $20.5B – $21.2B | $2.39 | 6 |
| 2028E | $24.5B | $18.2B – $27.2B | $2.89 | 6 |
Figures in USD · consensus as of November 1, 2026
Analyst Consensus
| Strong Buy | 0 |
| Buy | 4 |
| Hold | 8 |
| Sell | 1 |
| Strong Sell | 0 |
| Total analysts | 13 |
| Avg rating (−2 sell to +2 buy) | 0.23 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-05 | $-0.14 | ||
| 2026-08-06 | $1.10 | $0.40 | +173.0% |
| 2026-05-06 | $2.07 | $1.21 | +71.1% |
| 2026-02-10 | $-1.24 | $-0.92 | -34.6% |
| 2025-11-06 | $-0.53 | $-0.55 | +3.6% |
| 2025-08-06 | $-0.89 | $-0.90 | +1.1% |
| 2025-05-07 | $0.92 | $0.83 | +10.8% |
| 2025-02-04 | $-0.62 | $-0.55 | -12.7% |
Valuation Ratios
| P/E Ratio | 21.69 |
| Price / Book | 4.47 |
| EV / EBITDA | 6.68 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $553.8M | $589.6M | $1.92B | $4.13B | $5.86B | $9.18B | $11.70B |
| Cost of Revenue | 0 | 0 | 0 | 0 | $4.64B | $7.33B | $10.02B |
| Gross Profit | $553.8M | $589.6M | $1.92B | $4.13B | $1.22B | $1.84B | $1.68B |
| Research & Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | $110.7M | $166.7M | $265.1M | $1.42B | 0 | 0 | $2.05B |
| Operating Expenses | $813.2M | $995.4M | $2.49B | $4.74B | $1.46B | $1.79B | $2.08B |
| Operating Income | -$259.4M | -$405.8M | -$570.6M | -$610.1M | -$235.6M | $57.3M | -$396.4M |
| EBITDA | -$252.5M | -$391.0M | -$551.3M | -$572.2M | -$212.0M | $89.3M | -$391.1M |
| Interest Expense | 0 | $3.5M | $4.7M | $22.6M | $24.6M | $23.7M | $17.6M |
| Pre-tax Income | -$259.4M | -$405.8M | -$570.6M | -$610.1M | -$267.3M | $33.4M | -$437.3M |
| Income Tax | $1.8M | $1.0M | $846,000 | -$523,000 | $3.3M | $7.3M | $5.6M |
| Net Income | -$261.2M | -$406.8M | -$572.6M | -$606.3M | -$270.7M | $25.4M | -$443.2M |
| EPS | $-8.93 | $-1.70 | $-3.19 | $-2.85 | $-1.22 | $0.11 | $-1.69 |
| EPS (Diluted) | $-1.09 | $-1.70 | $-3.19 | $-2.85 | $-1.22 | $0.10 | $-1.69 |
| Shares Outstanding (Diluted) | 239.3 M | 239.3 M | 179.0 M | 212.5 M | 221.7 M | 265.9 M | 262.4 M |
Price
| Price | $30.37 (closing price, October 30, 2026) |
| Market Cap | $7.9B |
| Exchange | NYSE |
| Country | US |
Related companies: CLOV · CVS · CI · ELV · CNC · MOH
Explore sector: Healthcare · Medical - Healthcare Plans
More sections of OSCR: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks